Aerie Pharma (AERI) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Amazon (AMZN) Misses Q3 EPS by 7c, Misses on Revenue; Offers Q4 Revenue Guidance
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
Aerie Pharma (AERI) PT Lowered to $24 at Needham & Company
August 5, 2021 6:37 AM EDTNeedham & Company analyst Serge Belanger lowered the price target on Aerie Pharma (NASDAQ: AERI) to $24.00 (from $26.00) while maintaining a Buy rating.
The analyst commented, "AERI reported solid 2Q21 earnings with glaucoma sales of $27.2MM (+18%Q/Q and +51%Y/Y) that outpaced Street... More



